Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

David G. Maloney, MD PhD, Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, MD, Andres Forero, MD, Tina Albertson, MD, Jacob Garcia, MD, Daniel Li, PhD, Benhuai Xie, PhD, Tanya Siddiqi, MD

Blood (2017) 130 (Supplement 1): 1552.

https://doi.org/10.1182/blood.V130.Suppl_1.1552.1552

Published: 2017

Journal Articles

High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort

Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, MD, Andres Forero, MD, David G. Maloney, MD PhD, Tina Albertson, MD, Jacob Garcia, MD, Daniel Li, PhD, Benhuai Xie, PhD, Tanya Siddiqi, MD

Blood (2017) 130 (Supplement 1): 581.

https://doi.org/10.1182/blood.V130.Suppl_1.581.581

Published: 2017

Journal Articles

Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma

Noopur Raje, MD, Edward Anthony Faber, Jr., DO, MS, Paul G. Richardson, MD, Gary J. Schiller, MD, Raymond J. Hohl, MD, PhD, Adam D. Cohen, MD, Andres Forero, MD, Susan P. Carpenter, PhD, Damien Cronier, PhD, Christopher Kaiser, PhD, James E. Wooldridge, MD, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 447.

https://doi.org/10.1182/blood.V120.21.447.447

Published: 2012

Journal Articles

MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study

Blood (2012) 120 (21): 3677.

https://doi.org/10.1182/blood.V120.21.3677.3677

Published: 2012

Journal Articles

Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin's Lymphoma

Nathan H. Fowler, MD, Stephen P. Kahanic, MD, Andres Forero, MD, Mihaela C. Munteanu, MS, Glen L. Davis, MS, Peter Brown, DPhil, Eric Van Den Neste, MD, Fritz C. Offner, MD, PhD, Dominique Bron, MD, Myron S. Czuczman, MD

Blood (2011) 118 (21): 778.

https://doi.org/10.1182/blood.V118.21.778.778

Published: 2011

Journal Articles

Sustained Depletion of B-Cells by a Humanized, Fc-Engineered Anti-CD20 Antibody, AME-133v, in Patients with Relapsed Follicular Lymphoma

Jennifer Wayne, MS, Kristen N. Ganjoo, MD, Andres Forero, MD, Brad Pohlman, MD, Sven de Vos, MD, PhD, Susan P. Carpenter, PhD, James E Wooldridge, MD, Shashidhara Marulappa, DVM, MVSc, MBA, Vinay Jain, MBBS, MD, FACP

Blood (2011) 118 (21): 4977.

https://doi.org/10.1182/blood.V118.21.4977.4977

Published: 2011

Journal Articles

Phase I, Multicenter, Open Label, Dose Escalation of 90 yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma

Christos Vaklavas, MD, Ruby F Meredith, M.D., Ph.D., Susan J. Knox, MD, PhD, Gregory Wiseman, MD, Thomas E. Witzig, MD, Ivana N. Micallef, MD, Albert F. Lobuglio, MD, Andres Forero, MD

Blood (2011) 118 (21): 1648.

https://doi.org/10.1182/blood.V118.21.1648.1648

Published: 2011

NARROW

Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort

Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma

MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study

Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin's Lymphoma

Sustained Depletion of B-Cells by a Humanized, Fc-Engineered Anti-CD20 Antibody, AME-133v, in Patients with Relapsed Follicular Lymphoma

Phase I, Multicenter, Open Label, Dose Escalation of 90 yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort

Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma

MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study

Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin's Lymphoma

Sustained Depletion of B-Cells by a Humanized, Fc-Engineered Anti-CD20 Antibody, AME-133v, in Patients with Relapsed Follicular Lymphoma

Phase I, Multicenter, Open Label, Dose Escalation of 90 yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only